Natco Pharma gains on launching first generic version of Pomalyst Capsules in Australian market
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Natco Pharma is currently trading at Rs. 617.00, up by 3.80 points or 0.62% from its previous closing of Rs. 613.20 on the BSE.
The scrip opened at Rs. 609.05 and has touched a high and low of Rs. 617.35 and Rs. 609.05 respectively. So far 1317 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 942.15 on 17-Jan-2022 and a 52 week low of Rs. 582.75 on 21-Oct-2022.
Last one week high and low of the scrip stood at Rs. 628.80 and Rs. 609.05 respectively. The current market cap of the company is Rs. 11259.21 crore.
The promoters holding in the company stood at 48.80%, while Institutions and Non-Institutions held 25.97% and 25.23% respectively.
Natco Pharma has launched first generic version of Pomalyst (Pomalidomide) Capsules in 1,2,3,4 mg strengths in the Australian market. The product was launched by NATCO’s commercial partner Juno Pharmaceuticals. Pomalidomide is prescribed for treatment of Multiple Myeloma and Kaposi Sarcoma. Pomalyst registered sales of $35.6 million in the Australian market for the year ending March 31, 2022 as per industry sales data.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
